The inaugural event of the I to I Program was an investor survey created in collaboration between ISCT and Bloomberg Intelligence. The survey captured investor perceptions of key opportunities and challenges in the CGT field at the time. Survey results were published in a white paper in Cytotherapy, the Official Journal of ISCT.
Investor respondents of the ISCT-Bloomberg Intelligence survey were invited to a webinar hosted by Bloomberg featuring ISCT key opinion leaders (KOLs) Catherine Bollard, MD, MBChB (ISCT President 2016-2018), Bruce Levine, PhD (ISCT President 2020-2022), Ohad Karnieli, PhD, MBA (Past Co-Chair, ISCT Process and Product Development Subcommittee), Dawn Driscoll, PhD, MBA (Past Co-Chair, ISCT Market Access and Patient Advocacy Subcommittee) and Karen Nichols, Esq (ISCT Chief Regulatory Officer). Investors had the opportunity to ask the expert panel questions about the state of the industry, challenges, and opportunities for the field looking forward.
View webinar recording
Read the white paper